OKYO Pharma announced that its planned trial evaluating the efficacy and safety of OK-101 in subjects with DED has been posted on the ClinicalTrials.gov public website. ClinicalTrials.gov is a Web-based resource that provides patients, their family members, health care professionals, researchers, and the public with easy access to information on publicly and privately supported clinical studies on a wide range of diseases and conditions. OKYO is presently in the process of activating those clinical sites planned for the trial, and preparing the clinical trial drug product OK-101 for shipment to those sites involved in the double-blind, placebo-controlled trial, along with other activities needed for initiating the trial. OKYO is now anticipating the first-patient first-visit initiation of the trial in early Q2 and still looking to release top-line data from this trial in Q4.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on OKYO:
- OKYO Pharma Announces Phase 2 Trial of OK-101 Drug to Treat Dry Eye Disease is now listed on the ClinicalTrials.gov Public Website
- OKYO Pharma to issue 3.503M ADSs at $1.50 in private placement
- OKYO Pharma Limited announces U.S.$5.74 million Global Private Placement and investment by directors and members of senior management
- OKYO Pharma Limited Prices $5.3 Million Offering of ADSs
- OKYO Pharma announces OK-101 clears customs in the U.S.
